Amifostine Market by Product Type, Route of Administration, Application, End User - Global Forecast 2025-2030- Product Image

Sale

Amifostine Market by Product Type, Route of Administration, Application, End User - Global Forecast 2025-2030

Report
180 Pages
October 2024
Region: Global
360iResearch™
ID: 6014936

UP TO €665EUR$697USD£557GBP OFF until Dec 31^st 2024

The Amifostine Market grew from USD 503.25 million in 2023 to USD 543.28 million in 2024. It is expected to continue growing at a CAGR of 7.92%, reaching USD 858.37 million by 2030.

Amifostine, a cytoprotective drug primarily used to reduce the side effects of chemotherapy and radiation therapy, has found its relevance in cancer treatments, safeguarding normal tissues from damage. The necessity of Amifostine lies in its capability to mitigate the severe side effects of cancer treatment protocols, improving patient quality of life and treatment adherence. Its application extends primarily to oncology, where it acts as a protective agent for patients undergoing aggressive cancer therapies. End-use spans across hospitals, specialized cancer treatment centers, and research institutions focusing on advancing cancer treatment methodologies. Market growth for Amifostine is driven by increasing cancer prevalence, advancements in cancer treatment technologies, and an aging population. Moreover, the latest opportunities emerge from expanding applications of Amifostine beyond conventional cancer therapy, such as its potential in novel therapeutic areas and personalized cancer treatment protocols. Recommendations include leveraging research and development to explore these applications and developing strategic partnerships with cancer research institutions. However, limitations such as side effects, high cost of production, and stringent regulatory requirements pose challenges to market expansion. Additionally, competition from alternative cytoprotective and generic drugs, as well as lack of awareness in emerging markets, may hinder growth. Innovation and research might focus on developing Amifostine derivatives with enhanced efficacy and reduced toxicity, exploring its use as an adjuvant in novel cancer therapies, and utilizing it in combination with precision medicine to tailor protective measures for individual patients. The nature of the market remains competitive but promising, with significant emphasis on research and innovation to harness Amifostine's potential fully. Collaborating with oncologists and researchers to expand the scope of Amifostine in clinical trials could provide pathways for sustainable growth and wider acceptance in oncology practices.

Understanding Market Dynamics in the Amifostine Market

The Amifostine Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Growing awareness among healthcare professionals regarding the benefits of amifostine
- Expansion of healthcare infrastructure in emerging economies improving treatment access
- Increasing number of clinical trials focused on exploring new indications for amifostine
- Strategic partnerships and collaborations between pharmaceutical companies to enhance distribution
Market Restraints
- Limited awareness among healthcare providers and patients about the benefits of amifostine in oncology treatments
- High competition from alternative cytoprotective agents slowing the growth of the amifostine market
Market Opportunities
- Expanding the use of amifostine as a radioprotective agent in emerging cancer therapy protocols
- Leveraging amifostine in combination with new chemotherapeutic agents to enhance treatment efficacy and reduce side effects
- Increasing adoption of amifostine in pediatric oncology to minimize long-term radiotherapy and chemotherapy complications
Market Challenges
- Regulatory challenges concerning the approval of amifostine for new therapeutic uses pose significant delays
- Increasing competition from generic versions of amifostine leading to price reductions and market fragmentation

Exploring Porter’s Five Forces for the Amifostine Market

Porter’s Five Forces framework further strengthens the insights of the Amifostine Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Amifostine Market

External macro-environmental factors deeply influence the performance of the Amifostine Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Amifostine Market

The Amifostine Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Amifostine Market

The Amifostine Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Amifostine Market

The Amifostine Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Amifostine Market, highlighting leading vendors and their innovative profiles. These include Accela ChemBio Inc., Actiza Pharmaceutical Private Limited, Amneal Pharmaceuticals LLC, Athenex, Inc., Aurobindo Pharma Limited, Cadila Pharmaceuticals Ltd., Cipla Limited, Clinigen Group plc, Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Fresenius Kabi USA, LLC, Hikma Pharmaceuticals PLC, MedImmune LLC, Mylan N.V., Natco Pharma Limited, Shanxi Pude Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., West-Ward Pharmaceuticals Corp., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Amifostine Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product Type
- Injection
- Powder
Route of Administration
- Intravenous
- Subcutaneous
Application
- Oncology
  - Chemotherapy
  - Radiotherapy
- Renal Protection
  - Acute Kidney Injury
  - Chronic Kidney Disease
End User
- Homecare Settings
- Hospitals
- Research Institutes
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing awareness among healthcare professionals regarding the benefits of amifostine
5.1.1.2. Expansion of healthcare infrastructure in emerging economies improving treatment access
5.1.1.3. Increasing number of clinical trials focused on exploring new indications for amifostine
5.1.1.4. Strategic partnerships and collaborations between pharmaceutical companies to enhance distribution
5.1.2. Restraints
5.1.2.1. Limited awareness among healthcare providers and patients about the benefits of amifostine in oncology treatments
5.1.2.2. High competition from alternative cytoprotective agents slowing the growth of the amifostine market
5.1.3. Opportunities
5.1.3.1. Expanding the use of amifostine as a radioprotective agent in emerging cancer therapy protocols
5.1.3.2. Leveraging amifostine in combination with new chemotherapeutic agents to enhance treatment efficacy and reduce side effects
5.1.3.3. Increasing adoption of amifostine in pediatric oncology to minimize long-term radiotherapy and chemotherapy complications
5.1.4. Challenges
5.1.4.1. Regulatory challenges concerning the approval of amifostine for new therapeutic uses pose significant delays
5.1.4.2. Increasing competition from generic versions of amifostine leading to price reductions and market fragmentation
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Amifostine Market, by Product Type

6.1. Introduction
6.2. Injection
6.3. Powder

7. Amifostine Market, by Route of Administration

7.1. Introduction
7.2. Intravenous
7.3. Subcutaneous

8. Amifostine Market, by Application

8.1. Introduction
8.2. Oncology
8.2.1. Chemotherapy
8.2.2. Radiotherapy
8.3. Renal Protection
8.3.1. Acute Kidney Injury
8.3.2. Chronic Kidney Disease

9. Amifostine Market, by End User

9.1. Introduction
9.2. Homecare Settings
9.3. Hospitals
9.4. Research Institutes
9.5. Specialty Clinics

10. Americas Amifostine Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Amifostine Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Amifostine Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. AMIFOSTINE MARKET RESEARCH PROCESS
FIGURE 2. AMIFOSTINE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL AMIFOSTINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL AMIFOSTINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL AMIFOSTINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL AMIFOSTINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL AMIFOSTINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL AMIFOSTINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES AMIFOSTINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES AMIFOSTINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. AMIFOSTINE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. AMIFOSTINE MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. AMIFOSTINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL AMIFOSTINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AMIFOSTINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. AMIFOSTINE MARKET DYNAMICS
TABLE 7. GLOBAL AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AMIFOSTINE MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AMIFOSTINE MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AMIFOSTINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AMIFOSTINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AMIFOSTINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AMIFOSTINE MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AMIFOSTINE MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AMIFOSTINE MARKET SIZE, BY ACUTE KIDNEY INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AMIFOSTINE MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AMIFOSTINE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AMIFOSTINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AMIFOSTINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AMIFOSTINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. CANADA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 47. CANADA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. CANADA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 50. CANADA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 51. CANADA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. MEXICO AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. MEXICO AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. MEXICO AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. MEXICO AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 56. MEXICO AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES AMIFOSTINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. CHINA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 79. CHINA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. CHINA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. CHINA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 82. CHINA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 83. CHINA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. INDIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. INDIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. INDIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. INDIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 88. INDIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 89. INDIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. JAPAN AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. JAPAN AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. JAPAN AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. JAPAN AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 100. JAPAN AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 101. JAPAN AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. MALAYSIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. MALAYSIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. MALAYSIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 106. MALAYSIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. PHILIPPINES AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 109. PHILIPPINES AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. PHILIPPINES AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. PHILIPPINES AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 112. PHILIPPINES AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. SINGAPORE AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. SINGAPORE AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. SINGAPORE AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. SINGAPORE AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 118. SINGAPORE AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. SOUTH KOREA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 121. SOUTH KOREA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. SOUTH KOREA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. SOUTH KOREA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 124. SOUTH KOREA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. TAIWAN AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. TAIWAN AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. TAIWAN AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 130. TAIWAN AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. THAILAND AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 133. THAILAND AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. THAILAND AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. THAILAND AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 136. THAILAND AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 137. THAILAND AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. VIETNAM AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 139. VIETNAM AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 151. DENMARK AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 152. DENMARK AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. DENMARK AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. DENMARK AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 155. DENMARK AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 156. DENMARK AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. EGYPT AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. EGYPT AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. EGYPT AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. EGYPT AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 161. EGYPT AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 162. EGYPT AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. FINLAND AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. FINLAND AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. FINLAND AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. FINLAND AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 167. FINLAND AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 168. FINLAND AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. FRANCE AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 170. FRANCE AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. FRANCE AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. FRANCE AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 173. FRANCE AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 174. FRANCE AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. GERMANY AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 176. GERMANY AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. GERMANY AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. GERMANY AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 179. GERMANY AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 180. GERMANY AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. ITALY AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 188. ITALY AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. ITALY AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. ITALY AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 191. ITALY AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 192. ITALY AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. NIGERIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 200. NIGERIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. NORWAY AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. NORWAY AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. NORWAY AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. NORWAY AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 209. NORWAY AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 210. NORWAY AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. POLAND AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. POLAND AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. POLAND AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. POLAND AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 215. POLAND AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 216. POLAND AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. QATAR AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 218. QATAR AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. QATAR AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. QATAR AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 221. QATAR AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 222. QATAR AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. SPAIN AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. SPAIN AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. SPAIN AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. SPAIN AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 245. SPAIN AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 246. SPAIN AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. TURKEY AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 260. TURKEY AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. TURKEY AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 262. TURKEY AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 263. TURKEY AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 264. TURKEY AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. AMIFOSTINE MARKET SHARE, BY KEY PLAYER, 2023
TABLE 278. AMIFOSTINE MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Amifostine Market, which are profiled in this report, include:

Accela ChemBio Inc.
Actiza Pharmaceutical Private Limited
Amneal Pharmaceuticals LLC
Athenex, Inc.
Aurobindo Pharma Limited
Cadila Pharmaceuticals Ltd.
Cipla Limited
Clinigen Group plc
Dr. Reddy's Laboratories Ltd.
Eisai Co., Ltd.
Fresenius Kabi USA, LLC
Hikma Pharmaceuticals PLC
MedImmune LLC
Mylan N.V.
Natco Pharma Limited
Shanxi Pude Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
West-Ward Pharmaceuticals Corp.
Zydus Lifesciences Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	180
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 543.28 Million
Forecasted Market Value ( USD ) by 2030	$ 858.37 Million
Compound Annual Growth Rate	7.9%
Regions Covered	Global
No. of Companies Mentioned	21

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3382EUR$3,545USD£2,833GBP €3758EUR$3,939USD£3,148GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€5984EUR$6,272USD£5,013GBP €6649EUR$6,969USD£5,570GBP

Understanding Market Dynamics in the Amifostine Market

Exploring Porter’s Five Forces for the Amifostine Market

Applying PESTLE Analysis to the Amifostine Market

Analyzing Market Share in the Amifostine Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Amifostine Market

Strategic Recommendations for Success in the Amifostine Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Amifostine Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Product Type

Amifostine Hydrate Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

Amifostine (CAS 20537-88-6) Global Market Research Report 2024

Basal Cell Carcinoma Treatment Market by Type, Route of Administration, Clinical Variant, End-Users - Global Forecast 2025-2030

Extensive Stage Small Cell Lung Cancer Market by Treatment Modalities, Drug Type, Route of Administration, Distribution Channel - Global Forecast 2025-2030